Navigation Links
Intravenous (IV) Administration of Cempra Pharmaceutical's Solithromycin (CEM-101) Demonstrates Excellent Systemic Tolerability in a Phase 1 Clinical Trial
Date:5/7/2011

a Phase 2 clinical trial for serious community-acquired bacterial pneumonia or CABP," said David Oldach, M.D., vice president of clinical research at Cempra.  "This drug could be the first macrolide since azithromycin to offer both oral and intravenous forms of administration.  This will enable in-hospital treatment of seriously ill patients and will make possible IV to oral step-down therapy, shortening hospital stays.  We are excited about this compound because of its broad spectrum of activity including macrolide-resistant strains, its greater potency than existing macrolides and its dosing flexibility.  We look forward to advancing both IV and oral forms into the next stages of clinical development."

Solithromycin (CEM-101)

Solithromycin has shown a broad spectrum of activity and high potency against respiratory and other serious pathogens in in vitro and in vivo studies.  In vitro data from two studies presented at the conference showed that solithromycin exhibited high potency against European strains associated with CABP and exhibited stronger activity against Haemophilus influenzae compared to telithromycin.  

Biedenbach et al. (Abst. P1136) evaluated the activity of solithromycin against more than 6,300 isolates collected from 18 European countries in 2010.  Activity was tested against pathogens associated with CABP and acute bacterial skin and skin structure infections (ABSSSI), such as Staphylococcus aureus (including MRSA), coagulase-negative staphylococci, enterococci, Streptococcus pneumoniae, Streptococcus viridians, beta-haemolytic streptococci, H. influenzae and Moraxella catarrhalis.  Solithromycin exhibited greater potency than telithromycin and clindamycin against these contemporary
'/>"/>

SOURCE Cempra Pharmaceuticals
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Marshall Edwards Announces Publication of Phase II Clinical Trial Results Highlighting Activity of Intravenous Phenoxodiol
2. New Model Provides Insights Into Intravenous and Subcutaneous Immunoglobulin Pharmacokinetics in Patients With Primary Immunodeficiencies
3. Jennerex and Transgene Announce Initiation of Clinical Trial of Intravenous JX-594 in Patients With Refractory Metastatic Colorectal Cancer
4. Reportlinker Adds Global Intravenous (IV) Iron Drugs Industry
5. Hospira to Standardize Intravenous (I.V.) Administration Sets Portfolio to Non-DEHP
6. Reportlinker Adds Intravenous Equipment - A World Market Intelligence Report
7. Cadence Pharmaceuticals Announces FDA Extends New Drug Application Review for Intravenous Acetaminophen by Three Months
8. Iontophoretic Drug Delivery System (IDDS) Containing Lidocaine and Epinephrine is Effective in Reducing Pain Associated With Insertion of an Intravenous Catheter in a Phase 2 Clinical Trial
9. Calixa Therapeutics Announces Positive Phase 1 Results for CXA-101, a Novel Intravenous Cephalosporin Antibiotic with Excellent Anti-Pseudomonal Activity
10. Pivotal Phase III Data Confirm the Efficacy and Safety of Arpidas Intravenous Iclaprim in Treating Patients With Complicated Skin and Skin Structure Infections
11. Jennerex Completes the Treatment of First Patient Cohort in Phase 1 Trial With Intravenous Delivery of JX-594 Oncolytic Virus
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... , July 25, 2014 Research and ... "Global Ophthalmic Diagnostic Devices Market 2014-2018" report to ... About Ophthalmic Diagnostic Device ... to identify a defect or deficiency in the human ... ophthalmic disorders such as presbyopia, cataracts, glaucoma, retinal disorders, ...
(Date:7/25/2014)... , July 25, 2014 Leading events ... is returning for the seventh year to São Paulo, ... th August 2014. The event will co-locate with Food ... most comprehensive meeting point for the pharmaceutical industry. ... 25 countries for pharmaceutical sales are now exploring the ...
(Date:7/24/2014)... Calif. , July 24, 2014   AcelRx ... pharmaceutical company focused on the development and commercialization of ... pain, today confirmed the PDUFA date for Zalviso remains ... that a rumor circulated online stating the Food and ... 24, 2014 there has been no notification to the ...
Breaking Medicine Technology:Global Ophthalmic Diagnostic Devices Market 2014-2018: Key Vendors are Alcon, Carl Zeiss, Haag-Streit and Topcon 2CPhI South America 2014 Launches with Generics Showing Huge Growth 2CPhI South America 2014 Launches with Generics Showing Huge Growth 3CPhI South America 2014 Launches with Generics Showing Huge Growth 4AcelRx Pharmaceuticals Confirms July 27, 2014 PDUFA Date for Zalviso 2
... BOSTON, Dec. 9 Solos Endoscopy, Inc. (Pink Sheets: SNDY) ... sales for the month of October 2009 and $42,898.42 in ... October 2008 and $32,028.52 for November 2008 respectively. , About ... instrument company whose mission is to develop and market breakthrough ...
... , , , GAITHERSBURG, Md, ... in the development and manufacture of lentiviral gene delivery ... Institutes of Health (NIH) small business innovation research (SBIR) ... Generating Hepatitis C Virus-Like Particles using Lentivirus". In ...
Cached Medicine Technology:Lentigen Awarded Phase I SBIR Grant for Hepatitis C Vaccine 2
(Date:7/27/2014)... 2014 The constant expansion of companies ... demand for enterprise video. Additional factors that have increased ... areas such as corporate communication, learning and development, security ... all these factors the enterprise video market value has ... reach $35.57 billion in 2018 with a compound annual ...
(Date:7/27/2014)... 27, 2014 The North American security ... at $1570 million in 2014, and it is expected ... of 4.64%. The report incorporates the factors that influence ... of growth rates and projected total expenditure. The report ... global markets. Apart from the general overview of the ...
(Date:7/27/2014)... York City (Sunday July 27 11:45 am ... operationsinfection at the surgical sitehas been reduced by ... participation in the American College of Surgeons National ... a new case study presented at the 2014 ... Vancouver, British Columbia, reportedly reduced its rate of ...
(Date:7/27/2014)... The report provides market analysis ... Market Analysis (Commercial Aviation And Defense Aviation Landing ... - Forecasts 2014 - 2019." The report covers ... shape the market during the study period. It ... that are currently prevailing in the global market. ...
(Date:7/27/2014)... 2014 As Tylenol lawsuits ... move forward in federal court, Bernstein Liebhard LLP ... of the benefits purportedly associated with acetaminophen, the ... which appears in the The Lancet, looked at ... whom were given either acetaminophen or a placebo ...
Breaking Medicine News(10 mins):Health News:North America Enterprise Video Market is Expected to Reach $13.00 billion in 2018 - New Report by MicroMarket Monitor 2Health News:North America Enterprise Video Market is Expected to Reach $13.00 billion in 2018 - New Report by MicroMarket Monitor 3Health News:North America Enterprise Video Market is Expected to Reach $13.00 billion in 2018 - New Report by MicroMarket Monitor 4Health News:North America Security and Surveillance Radar Market is Expected to Reach $2030 million in 2019 - New Report by MicroMarket Monitor 2Health News:North America Security and Surveillance Radar Market is Expected to Reach $2030 million in 2019 - New Report by MicroMarket Monitor 3Health News:North America Security and Surveillance Radar Market is Expected to Reach $2030 million in 2019 - New Report by MicroMarket Monitor 4Health News:North America Security and Surveillance Radar Market is Expected to Reach $2030 million in 2019 - New Report by MicroMarket Monitor 5Health News:Surgical safety program greatly reduces surgical site infections for heart operations 2Health News:Surgical safety program greatly reduces surgical site infections for heart operations 3Health News:Surgical safety program greatly reduces surgical site infections for heart operations 4Health News:Actuator Systems Market in Aviation Estimated to Reach $3,839.74 Million by 2019 - New Report by MarketsandMarkets 2Health News:Actuator Systems Market in Aviation Estimated to Reach $3,839.74 Million by 2019 - New Report by MarketsandMarkets 3Health News:Actuator Systems Market in Aviation Estimated to Reach $3,839.74 Million by 2019 - New Report by MarketsandMarkets 4Health News:As Tylenol Lawsuits Mount, Bernstein Liebhard LLP Notes Study Questioning Some Benefits Purportedly Associated with Acetaminophen 2Health News:As Tylenol Lawsuits Mount, Bernstein Liebhard LLP Notes Study Questioning Some Benefits Purportedly Associated with Acetaminophen 3Health News:As Tylenol Lawsuits Mount, Bernstein Liebhard LLP Notes Study Questioning Some Benefits Purportedly Associated with Acetaminophen 4
... 13 Berkery Noyes announced today that,the firm represented ... HCPro Holdings, Inc. to Halyard Capital. The management team ... Terms of the transaction,were not disclosed., "This is ... team with a winning healthcare and information franchise," said,Tom ...
... with glasses brought them up to snuff with ... News) -- Preschoolers with poor vision significantly improved ... wearing prescription glasses, a new study shows. , ... have early vision problems that are undiagnosed and ...
... Inc.,(Nasdaq: TSTF ), a national provider of ... has hired Jeff Davis as Director,of Operations for ... will be responsible for leading client field,operations and ... existing and new contracts. Mr. Davis will report ...
... Healthcare Industry to Follow Suit, WASHINGTON, Feb. ... to require all of its administrative,data-exchange vendors to ... Committee on Operating Rules for Information Exchange (CORE), ... electronic administrative data,exchange," said Ronald A. Williams, CAQH ...
... healthcare privacy auditing solutions, ... titled Addressing Electronic Health Record Privacy and ... HIMSS Chairman & Vice ... Robert Sullivan of PricewaterhouseCoopers, Healthcare Advisory ...
... Enters Into Marketing Partnership for Once-Daily Tramadol for ... ... Feb. 13 /PRNewswire-FirstCall/ - Labopharm Inc. (TSX: DDS;,NASDAQ: DDSS) today announced ... Food and Drug Administration,which allows for the marketing and sale of ...
Cached Medicine News:Health News:Berkery Noyes Represented The Riverside Company on the Sale of HCPro Holdings, Inc. to Halyard Capital, LLC 2Health News:Berkery Noyes Represented The Riverside Company on the Sale of HCPro Holdings, Inc. to Halyard Capital, LLC 3Health News:Fixing Poor Vision Boosts Preschoolers' Test Scores 2Health News:TeamStaff Hires Jeff Davis as Director of Operations for Government Solutions Subsidiary 2Health News:TeamStaff Hires Jeff Davis as Director of Operations for Government Solutions Subsidiary 3Health News:Aetna Requires CAQH Core Rules Certification for Vendors 2Health News:Aetna Requires CAQH Core Rules Certification for Vendors 3Health News:FairWarning to Host Webinar Featuring HIMSS Chairman and Healthcare Executive from PricewaterhouseCoopers on Electronic Health Record Privacy and Compliance Challenges 2Health News:Labopharm's Once-Daily Tramadol Approved in South Korea and Australia 2Health News:Labopharm's Once-Daily Tramadol Approved in South Korea and Australia 3
... objective and high power negative lens delivering ... true benefit of this system is ease ... is made possible due to a superior ... bar and individual interpupillary adjustment provides stability ...
GE's Signa Contour/i system uses the latest innovations from around the world to bring new standards in quality and value to MRI....
Signa Profile is built on the Signa foundation to deliver speed & image quality....
... Platelet Concentrate System is a point-of-care system ... Concentrate (also referred to as Platelet Rich ... (PPP) from a small sample of blood. ... growth factors, which are found in the ...
Medicine Products: